|
KMID : 0387820180250020102
|
|
Clinical Pediatric Hematology-Oncology
2018 Volume.25 No. 2 p.102 ~ p.107
|
|
|
The Efficacy of High Dose Dexamethasone Therapy in Children with Immune Thrombocytopenic Purpura
|
|
Lee Hyun-Ok
Chang Seong-Hwan
Baek Hee-Jo
Kim Ho-Sung
Park Su-Min
Shin Myung-Geun
Kook Hoon
|
|
|
Abstract
|
|
|
Background: Few studies of high dose dexamethasone (HD-DXM) therapy in children with immune thrombocytopenic purpura (ITP) have been reported. The purpose of this study is to investigate efficacy and safety of repeated HD-DXM therapy as second-line treatment of ITP in childhood.
Methods: We retrospectively analyzed the medical records of patients ＜18 years of age with primary ITP who received more than 2 cycles of HD-DXM therapy from May 2004 to January 2018. HD-DXM was given orally in 4-day pulses every 28 days as a 20-40 mg/1.73 m2 daily dose.
Results: A total of 26 patients (male, 19; female, 7) were enrolled and their median age was 6 years (range, 1-15). All patients had received previous treatment for ITP. A median 6 cycles (range, 2-19) of HD-DXM was given. On the beginning of HD-DXM therapy, three patients satisfied the criteria for newly diagnosed ITP, 16 for persistent ITP and 7 for chronic ITP. Relapse-free survival (RFS) of responders (n=9) after the last HD-DXM cycle was estimated to be 38.1±17.2%, lasting for a median 9.1 months (range, 5.6-46.2). According to response after the 2nd cycle, RFS of responders (n=13) was significantly higher than non-responders (23.1±11.7% vs. 7.7%±7.4%, P=0.001). The most common adverse event was irritability (30.8%), followed by fatigue (19.2%).
Conclusion: HD-DXM therapy in children was relatively tolerated and response after therapy was acceptable. More courses of HD-DXM may be feasible in responders after two cycles of HD-DXM.
|
|
|
KEYWORD
|
|
|
Immune thrombocytopenic purpura, High dose dexamethasone
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|